Abstract:With their capability to undergo unlimited self-renewal and to differentiate into all cell types in the body, induced pluripotent stem cells (iPSCs), reprogrammed from somatic cells of individual patients with defined factors, have unlimited potential in cell therapy and in modeling complex human diseases. Significant progress has been achieved to improve the safety of iPSCs and the reprogramming efficiency. To avoid the cancer risk and spontaneous reactivation of the reprogramming factors associated with the random integration of viral vectors into the genome, several approaches have been established to deliver the reprogramming factors into the somatic cells without inducing genetic modification. In addition, a panel of small molecule compounds, many of which targeting the epigenetic machinery, have been identified to increase the reprogramming efficiency. Despite these progresses, recent studies have identified genetic and epigenetic abnormalities of iPSCs as well as the immunogenicity of some cells derived from iPSCs. In addition, due to the oncogenic potential of the reprogramming factors and the reprogramming-induced DNA damage, the critical tumor suppressor pathways such as p53 and ARF are activated to act as the checkpoints that suppress induced pluripotency. The inactivation of these tumor suppression pathways even transiently during reprogramming processes could have significant adverse impact on the genome integrity. These safety concerns must be resolved to improve the feasibility of the clinic development of iPSCs into human cell therapy.

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells

Enhancement of Xrcc1-mediated Base Excision Repair Improves the Genetic Stability and Pluripotency of Ipscs

Increase Developmental Plasticity Of Human Keratinocytes With Gene Suppression

p53 isoform Δ133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Suppression of induced pluripotent stem cell generation by the p53–p21 pathway

Context‐Dependent Enhancement of Induced Pluripotent Stem Cell Reprogramming by Silencing Puma

Generation of Human-Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2

Brief Report: Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts

Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution

Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells

P53 Isoform Delta 133p53 Promotes Efficiency Of Induced Pluripotent Stem Cells And Ensures Genomic Integrity During Reprogramming

Two Supporting Factors Greatly Improve the Efficiency of Human Ipsc Generation

Efficient reprogramming of human fibroblasts using RNA reprogramming with DAPT and iDOT1L under normoxia conditions

p18 inhibits reprogramming through inactivation of Cdk4/6

Apoptosis inhibition enhances induced pluripotent stem cell generation during T cell reprogramming

A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation

The cytotoxic and immunogenic hurdles associated with non-viral mRNA-mediated reprogramming of human fibroblasts

Progress and Bottleneck in Induced Pluripotency.

Fine-tuning of iPSC derivation by an inducible reprogramming system at the protein level.

Mir-138 Promotes Induced Pluripotent Stem Cell Generation Through the Regulation of the P53 Signaling